1月16日，诚益通跌5.28%，截至发稿，报24.24元/股，成交1.74亿元，换手率2.69%，总市值66.19亿 元。 资料显示，北京诚益通控制技术集团股份有限公司位于北京市大兴区生物医药产业基地庆丰西路27号， 成立日期2003年7月22日，上市日期2015年3月19日，公司主营业务涉及提供医药、生物工业自动化控制 系统整体解决方案;康复理疗医疗器械的研发、生产和销售业务。主营业务收入构成为：控制系统 54.65%，康复医疗器械28.89%，系统设备及其他16.47%。 从诚益通十大流通股东角度 数据显示，长城基金旗下1只基金位居诚益通十大流通股东。长城消费增值混合A（200006）三季度新 进十大流通股东，持有股数200万股，占流通股的比例为0.77%。根据测算，今日浮亏损失约270万元。 长城消费增值混合A（200006）成立日期2006年4月6日，最新规模5.16亿。今年以来收益21.73%，同类 排名56/8847；近一年收益44.1%，同类排名2734/8094；成立以来收益315.35%。 长城消费增值混合A（200006）基金经理为龙宇飞。 截至发稿，龙宇飞累计任职时间8年93天，现任基金 ...

12月19日，诚益通盘中上涨2.09%，截至13:00，报19.05元/股，成交5755.27万元，换手率1.18%，总市 值52.02亿元。 资金流向方面，主力资金净流出99.62万元，大单买入624.62万元，占比10.85%，卖出724.24万元，占比 12.58%。 分红方面，诚益通A股上市后累计派现8055.38万元。近三年，累计派现3960.21万元。 机构持仓方面，截止2025年9月30日，诚益通十大流通股东中，长城消费增值混合A（200006）位居第 五大流通股东，持股200.00万股，为新进股东。广发聚丰混合A（270005）位居第八大流通股东，持股 133.07万股，为新进股东。广发优势成长股票A（011425）位居第十大流通股东，持股100.79万股，为 新进股东。华夏领先股票（001042）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，北京诚益通控制技术集团股份有限公司位于北京市大兴区生物医药产业基地庆丰西路27号， 成立日期2003年7月22日，上市日期2015年3月19日，公司主营业务涉及提供医药、生物工业自动化控制 系统整体解决方案;康复理疗医疗器械的研发、生产和销售业务 ...

Company Overview - Cheng Yi Tong, established on July 22, 2003, and listed on March 19, 2015, is located in Beijing's Daxing District and specializes in providing overall solutions for pharmaceutical and biological industrial automation control systems, as well as the research, production, and sales of rehabilitation medical devices [1][2]. Financial Performance - For the first half of 2025, Cheng Yi Tong reported a revenue of 408 million yuan, a year-on-year decrease of 36.65%, and a net profit attributable to shareholders of 51.18 million yuan, down 38.76% year-on-year [2]. - The company has cumulatively distributed 80.55 million yuan in dividends since its A-share listing, with 39.60 million yuan distributed over the past three years [3]. Stock Performance - As of October 16, Cheng Yi Tong's stock price increased by 2.08% to 20.57 yuan per share, with a total market capitalization of 5.617 billion yuan [1]. - Year-to-date, the stock price has risen by 34.84%, with a 2.03% increase over the last five trading days, a 3.79% decrease over the last 20 days, and a 3.58% increase over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 11.71% to 32,700, while the average number of circulating shares per person decreased by 10.48% to 7,952 shares [2][3]. - Among the top ten circulating shareholders, Huaxia Leading Stock (001042) ranked eighth with 1.4626 million shares, an increase of 80,400 shares compared to the previous period [3].

Core Viewpoint - The stock price of Chengyitong has shown a year-to-date increase of 28.48%, but has recently experienced declines over various time frames, indicating potential volatility in the market [2]. Group 1: Stock Performance - As of October 14, Chengyitong's stock price decreased by 2.05%, trading at 19.60 CNY per share with a total market capitalization of 5.352 billion CNY [1]. - The stock has declined by 1.85% over the last five trading days, 9.68% over the last 20 days, and 4.34% over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Chengyitong reported a revenue of 408 million CNY, representing a year-on-year decrease of 36.65%, while the net profit attributable to shareholders was 51.18 million CNY, down 38.76% year-on-year [2]. - The company has distributed a total of 80.55 million CNY in dividends since its A-share listing, with 39.60 million CNY distributed over the last three years [3]. Group 3: Business Overview - Chengyitong, established on July 22, 2003, and listed on March 19, 2015, specializes in providing automation control solutions for the pharmaceutical and biotechnology industries, as well as the research, production, and sales of rehabilitation medical devices [2]. - The company's revenue composition includes 54.65% from control systems, 28.89% from rehabilitation medical devices, and 16.47% from system equipment and others [2]. - Chengyitong is categorized under the machinery and equipment industry, specifically in general equipment and other general equipment sectors, with involvement in various concept sectors such as pet economy, traditional Chinese medicine, synthetic biology, multiple births, and elderly care [2]. Group 4: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 11.71% to 32,700, with an average of 7,952 circulating shares per person, a decrease of 10.48% [2]. - Among the top ten circulating shareholders, Huaxia Leading Stock (001042) ranked eighth with 1.4626 million shares, an increase of 80,400 shares compared to the previous period [3].